vorinostat (Rx)

Brand and Other Names:Zolinza
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

capsule

  • 100mg

Cutaneous T-cell Lymphoma

Indicated for treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma who have progressive, persistent, or recurrent disease during or following 2 systemic therapies

400 mg PO qDay

May reduce to 300 mg qDay, and then to 300 mg qDay for 5 days/wk if intolerant

Monitor: CBC, electrolytes, serum glucose and creatinine q2week during first 2 months and monthly thereafter

Dosage Modifications

Hepatic impairment

  • Mild/moderate (Child-Pugh A or B): Use with caution
  • Severe (Child-Pugh C): Contraindicated

Multiple Myeloma (Orphan)

Orphan designation for treatment of multiple myeloma

Sponsor

  • Merck Research Laboratories; Merck & Co Inc; PO Box 2000, RY 33-212; Rahway, NJ 07065-0900

Melanoma (Orphan)

Orphan designation for treatment of advanced melanoma (stages IIb, IIc, III, and IV)

Sponsor

  • Qameleon Therapeutics; Moslaan 32, 1433 WJ; Kudelstaart, Netherlands

Safety and efficacy not established

Next:

Interactions

Interaction Checker

and vorinostat

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 

            Contraindicated (2)

            • dronedarone

              vorinostat and dronedarone both increase QTc interval. Contraindicated.

            • thioridazine

              vorinostat and thioridazine both increase QTc interval. Contraindicated.

            Serious - Use Alternative (76)

            • amiodarone

              vorinostat and amiodarone both increase QTc interval. Avoid or Use Alternate Drug.

            • amisulpride

              amisulpride and vorinostat both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • anagrelide

              anagrelide and vorinostat both increase QTc interval. Avoid or Use Alternate Drug.

              vorinostat and anagrelide both increase QTc interval. Avoid or Use Alternate Drug.

            • aripiprazole

              aripiprazole and vorinostat both increase QTc interval. Avoid or Use Alternate Drug.

            • arsenic trioxide

              vorinostat and arsenic trioxide both increase QTc interval. Avoid or Use Alternate Drug.

            • artemether

              artemether and vorinostat both increase QTc interval. Avoid or Use Alternate Drug.

            • artemether/lumefantrine

              vorinostat and artemether/lumefantrine both increase QTc interval. Avoid or Use Alternate Drug.

            • asenapine

              asenapine and vorinostat both increase QTc interval. Avoid or Use Alternate Drug.

              vorinostat and asenapine both increase QTc interval. Avoid or Use Alternate Drug.

            • asenapine transdermal

              asenapine transdermal and vorinostat both increase QTc interval. Avoid or Use Alternate Drug.

            • buprenorphine

              vorinostat and buprenorphine both increase QTc interval. Avoid or Use Alternate Drug.

              buprenorphine and vorinostat both increase QTc interval. Avoid or Use Alternate Drug.

            • ceritinib

              ceritinib and vorinostat both increase QTc interval. Avoid or Use Alternate Drug.

            • chlorpromazine

              vorinostat and chlorpromazine both increase QTc interval. Avoid or Use Alternate Drug.

            • citalopram

              citalopram and vorinostat both increase QTc interval. Avoid or Use Alternate Drug.

            • clarithromycin

              clarithromycin and vorinostat both increase QTc interval. Avoid or Use Alternate Drug.

            • clozapine

              clozapine and vorinostat both increase QTc interval. Avoid or Use Alternate Drug.

            • deferiprone

              deferiprone, vorinostat. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Avoid use of deferiprone with other drugs known to be associated with neutropenia or agranulocytosis; if an alternative is not possible, monitor absolute neutrophil count more frequently.

            • desflurane

              desflurane and vorinostat both increase QTc interval. Avoid or Use Alternate Drug.

            • disopyramide

              vorinostat and disopyramide both increase QTc interval. Avoid or Use Alternate Drug.

            • dofetilide

              dofetilide increases toxicity of vorinostat by QTc interval. Avoid or Use Alternate Drug.

            • droperidol

              vorinostat and droperidol both increase QTc interval. Avoid or Use Alternate Drug.

            • eliglustat

              vorinostat and eliglustat both increase QTc interval. Avoid or Use Alternate Drug.

            • encorafenib

              encorafenib and vorinostat both increase QTc interval. Avoid or Use Alternate Drug.

            • entrectinib

              entrectinib and vorinostat both increase QTc interval. Avoid or Use Alternate Drug.

            • eribulin

              eribulin and vorinostat both increase QTc interval. Avoid or Use Alternate Drug.

            • erythromycin base

              vorinostat and erythromycin base both increase QTc interval. Avoid or Use Alternate Drug.

            • erythromycin ethylsuccinate

              vorinostat and erythromycin ethylsuccinate both increase QTc interval. Avoid or Use Alternate Drug.

            • erythromycin lactobionate

              vorinostat and erythromycin lactobionate both increase QTc interval. Avoid or Use Alternate Drug.

            • erythromycin stearate

              vorinostat and erythromycin stearate both increase QTc interval. Avoid or Use Alternate Drug.

            • fexinidazole

              fexinidazole and vorinostat both increase QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of fexinidazole with drugs known to block potassium channels or prolong QT interval.

            • foscarnet

              vorinostat and foscarnet both increase QTc interval. Avoid or Use Alternate Drug.

            • glasdegib

              vorinostat and glasdegib both increase QTc interval. Avoid or Use Alternate Drug.

            • hydroxychloroquine sulfate

              hydroxychloroquine sulfate and vorinostat both increase QTc interval. Avoid or Use Alternate Drug.

            • ibutilide

              vorinostat and ibutilide both increase QTc interval. Avoid or Use Alternate Drug.

            • iloperidone

              vorinostat and iloperidone both increase QTc interval. Avoid or Use Alternate Drug.

            • inotuzumab

              vorinostat and inotuzumab both increase QTc interval. Avoid or Use Alternate Drug.

            • isoflurane

              isoflurane and vorinostat both increase QTc interval. Avoid or Use Alternate Drug.

            • ivosidenib

              ivosidenib and vorinostat both increase QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of QTc prolonging drugs with ivosidenib or replace with alternate therapies. If coadministration of a QTc prolonging drug is unavoidable, monitor for increased risk of QTc interval prolongation.

            • lefamulin

              lefamulin and vorinostat both increase QTc interval. Avoid or Use Alternate Drug.

            • lenvatinib

              vorinostat and lenvatinib both increase QTc interval. Avoid or Use Alternate Drug.

            • lofexidine

              vorinostat and lofexidine both increase QTc interval. Avoid or Use Alternate Drug.

            • lopinavir

              vorinostat and lopinavir both increase QTc interval. Avoid or Use Alternate Drug.

            • macimorelin

              macimorelin and vorinostat both increase QTc interval. Avoid or Use Alternate Drug. Macimorelin causes an increase of ~11 msec in the corrected QT interval. Avoid coadministration with drugs that prolong QT interval, which could increase risk for developing torsade de pointes-type ventricular tachycardia. Allow sufficient washout time of drugs that are known to prolong the QT interval before administering macimorelin.

            • maprotiline

              vorinostat and maprotiline both increase QTc interval. Avoid or Use Alternate Drug.

            • mefloquine

              mefloquine increases toxicity of vorinostat by QTc interval. Avoid or Use Alternate Drug. Mefloquine may enhance the QTc prolonging effect of high risk QTc prolonging agents.

            • methadone

              vorinostat and methadone both increase QTc interval. Avoid or Use Alternate Drug.

            • midostaurin

              vorinostat and midostaurin both increase QTc interval. Avoid or Use Alternate Drug.

            • mobocertinib

              mobocertinib and vorinostat both increase QTc interval. Avoid or Use Alternate Drug. If coadministration unavoidable, reduce mobocertinib dose and monitor QTc interval more frequently.

            • moxifloxacin

              vorinostat and moxifloxacin both increase QTc interval. Avoid or Use Alternate Drug.

            • nilotinib

              vorinostat and nilotinib both increase QTc interval. Avoid or Use Alternate Drug.

            • ondansetron

              ondansetron and vorinostat both increase QTc interval. Avoid or Use Alternate Drug. Avoid with congenital long QT syndrome; ECG monitoring recommended with concomitant medications that prolong QT interval, electrolyte abnormalities, CHF, or bradyarrhythmias.

            • oxaliplatin

              oxaliplatin and vorinostat both increase QTc interval. Avoid or Use Alternate Drug.

            • palifermin

              palifermin increases toxicity of vorinostat by Other (see comment). Avoid or Use Alternate Drug. Comment: Palifermin should not be administered within 24 hr before, during infusion of, or within 24 hr after administration of antineoplastic agents. Coadministration of palifermin within 24 hr of chemotherapy resulted in increased severity and duration of oral mucositis.

            • paliperidone

              vorinostat and paliperidone both increase QTc interval. Avoid or Use Alternate Drug.

            • panobinostat

              vorinostat and panobinostat both increase QTc interval. Avoid or Use Alternate Drug.

            • pazopanib

              vorinostat and pazopanib both increase QTc interval. Avoid or Use Alternate Drug.

            • pentamidine

              vorinostat and pentamidine both increase QTc interval. Avoid or Use Alternate Drug.

            • pimavanserin

              vorinostat and pimavanserin both increase QTc interval. Avoid or Use Alternate Drug.

            • pimozide

              vorinostat and pimozide both increase QTc interval. Contraindicated.

            • pitolisant

              vorinostat and pitolisant both increase QTc interval. Avoid or Use Alternate Drug.

            • ponesimod

              vorinostat and ponesimod both increase QTc interval. Avoid or Use Alternate Drug.

            • propafenone

              vorinostat and propafenone both increase QTc interval. Avoid or Use Alternate Drug.

            • quinidine

              vorinostat and quinidine both increase QTc interval. Avoid or Use Alternate Drug.

            • ribociclib

              ribociclib increases toxicity of vorinostat by QTc interval. Avoid or Use Alternate Drug.

            • ropeginterferon alfa 2b

              ropeginterferon alfa 2b, vorinostat. Either increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression.

            • saquinavir

              vorinostat and saquinavir both increase QTc interval. Avoid or Use Alternate Drug.

            • sevoflurane

              sevoflurane and vorinostat both increase QTc interval. Avoid or Use Alternate Drug.

            • siponimod

              siponimod and vorinostat both increase QTc interval. Avoid or Use Alternate Drug.

            • sotalol

              vorinostat and sotalol both increase QTc interval. Avoid or Use Alternate Drug.

            • tetrabenazine

              vorinostat and tetrabenazine both increase QTc interval. Avoid or Use Alternate Drug.

            • toremifene

              vorinostat and toremifene both increase QTc interval. Avoid or Use Alternate Drug.

            • trazodone

              vorinostat and trazodone both increase QTc interval. Avoid or Use Alternate Drug.

            • umeclidinium bromide/vilanterol inhaled

              vorinostat increases toxicity of umeclidinium bromide/vilanterol inhaled by QTc interval. Avoid or Use Alternate Drug. Exercise extreme caution when vilanterol coadministered with drugs that prolong QTc interval; adrenergic agonist effects on the cardiovascular system may be potentiated.

            • valproic acid

              vorinostat, valproic acid. pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of severe thrombocytopenia and GI bleeding. Monitor platelet count q 2 wks for first 2 months.

            • vandetanib

              vorinostat, vandetanib. Either increases toxicity of the other by QTc interval. Avoid or Use Alternate Drug. Avoid coadministration with drugs known to prolong QT interval; if a drug known to prolong QT interval must be used, more frequent ECG monitoring is recommended.

            • vemurafenib

              vemurafenib and vorinostat both increase QTc interval. Avoid or Use Alternate Drug. Concomitant use of vemurafenib with drugs that prolong QT interval is not recommended.

            • ziprasidone

              vorinostat and ziprasidone both increase QTc interval. Avoid or Use Alternate Drug.

            Monitor Closely (83)

            • albuterol

              albuterol and vorinostat both increase QTc interval. Use Caution/Monitor.

            • alfuzosin

              vorinostat and alfuzosin both increase QTc interval. Use Caution/Monitor.

              alfuzosin and vorinostat both increase QTc interval. Use Caution/Monitor.

            • apomorphine

              apomorphine and vorinostat both increase QTc interval. Use Caution/Monitor.

            • arformoterol

              arformoterol and vorinostat both increase QTc interval. Use Caution/Monitor.

            • atomoxetine

              atomoxetine and vorinostat both increase QTc interval. Use Caution/Monitor.

            • bedaquiline

              vorinostat and bedaquiline both increase QTc interval. Modify Therapy/Monitor Closely. ECG should be monitored closely

            • cholera vaccine

              vorinostat decreases effects of cholera vaccine by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs and corticosteroids (used in greater than physiologic doses), may reduce the immune response to cholera vaccine.

            • ciprofloxacin

              vorinostat and ciprofloxacin both increase QTc interval. Use Caution/Monitor.

            • citalopram

              vorinostat and citalopram both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.

            • crizotinib

              crizotinib and vorinostat both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.

            • dasatinib

              dasatinib and vorinostat both increase QTc interval. Use Caution/Monitor.

            • degarelix

              degarelix and vorinostat both increase QTc interval. Use Caution/Monitor.

            • dengue vaccine

              vorinostat decreases effects of dengue vaccine by immunosuppressive effects; risk of infection. Use Caution/Monitor. Immunosuppressive therapies (eg, irradiation, antimetabolites, alkylating agents, cytotoxic drugs, corticosteroids [greater than physiologic doses]) may reduce immune response to dengue vaccine.

            • deutetrabenazine

              deutetrabenazine and vorinostat both increase QTc interval. Use Caution/Monitor. At the maximum recommended dose, deutetrabenazine does not prolong QT interval to a clinically relevant extent. Certain circumstances may increase risk of torsade de pointes and/or sudden death in association with drugs that prolong the QTc interval (eg, bradycardia, hypokalemia or hypomagnesemia, coadministration with other drugs that prolong QTc interval, presence of congenital QT prolongation).

            • dichlorphenamide

              dichlorphenamide and vorinostat both decrease serum potassium. Use Caution/Monitor.

            • dolasetron

              dolasetron and vorinostat both increase QTc interval. Use Caution/Monitor.

            • donepezil

              donepezil and vorinostat both increase QTc interval. Use Caution/Monitor.

            • doxepin

              doxepin and vorinostat both increase QTc interval. Use Caution/Monitor.

            • efavirenz

              efavirenz and vorinostat both increase QTc interval. Use Caution/Monitor.

            • escitalopram

              escitalopram increases toxicity of vorinostat by QTc interval. Use Caution/Monitor.

            • ezogabine

              ezogabine, vorinostat. Either increases toxicity of the other by QTc interval. Use Caution/Monitor. Slight and transient QT-prolongation observed with ezogabine, particularly when dose titrated to 1200 mg/day. QT interval should be monitored when ezogabine is prescribed with agents known to increase QT interval.

            • fingolimod

              fingolimod and vorinostat both increase QTc interval. Use Caution/Monitor.

            • flecainide

              vorinostat and flecainide both increase QTc interval. Use Caution/Monitor.

            • fluconazole

              vorinostat and fluconazole both increase QTc interval. Use Caution/Monitor.

            • fluoxetine

              vorinostat and fluoxetine both increase QTc interval. Modify Therapy/Monitor Closely.

            • fluphenazine

              vorinostat and fluphenazine both increase QTc interval. Use Caution/Monitor.

            • fluvoxamine

              vorinostat and fluvoxamine both increase QTc interval. Use Caution/Monitor.

            • fostemsavir

              vorinostat and fostemsavir both increase QTc interval. Use Caution/Monitor.

            • gemifloxacin

              gemifloxacin and vorinostat both increase QTc interval. Use Caution/Monitor.

            • gemtuzumab

              vorinostat and gemtuzumab both increase QTc interval. Use Caution/Monitor.

            • gilteritinib

              gilteritinib and vorinostat both increase QTc interval. Use Caution/Monitor.

            • goserelin

              vorinostat and goserelin both increase QTc interval. Use Caution/Monitor.

            • granisetron

              granisetron and vorinostat both increase QTc interval. Use Caution/Monitor.

            • haloperidol

              haloperidol and vorinostat both increase QTc interval. Use Caution/Monitor.

            • histrelin

              vorinostat and histrelin both increase QTc interval. Use Caution/Monitor.

            • hydroxyzine

              hydroxyzine and vorinostat both increase QTc interval. Use Caution/Monitor.

            • indacaterol, inhaled

              indacaterol, inhaled, vorinostat. QTc interval. Use Caution/Monitor. Drugs that are known to prolong the QTc interval may have an increased the risk of ventricular arrhythmias.

            • itraconazole

              itraconazole and vorinostat both increase QTc interval. Use Caution/Monitor.

            • lapatinib

              vorinostat and lapatinib both increase QTc interval. Use Caution/Monitor.

            • leuprolide

              vorinostat and leuprolide both increase QTc interval. Use Caution/Monitor.

            • levofloxacin

              vorinostat and levofloxacin both increase QTc interval. Use Caution/Monitor.

            • lithium

              lithium and vorinostat both increase QTc interval. Use Caution/Monitor.

            • loperamide

              vorinostat and loperamide both increase QTc interval. Use Caution/Monitor.

            • metformin

              vorinostat decreases effects of metformin by pharmacodynamic antagonism. Use Caution/Monitor.

            • mifepristone

              mifepristone, vorinostat. QTc interval. Modify Therapy/Monitor Closely. Use alternatives if available.

            • mirtazapine

              mirtazapine and vorinostat both increase QTc interval. Use Caution/Monitor.

            • octreotide

              vorinostat and octreotide both increase QTc interval. Use Caution/Monitor.

            • ofloxacin

              vorinostat and ofloxacin both increase QTc interval. Use Caution/Monitor.

            • olanzapine

              olanzapine and vorinostat both increase QTc interval. Use Caution/Monitor.

            • olodaterol inhaled

              vorinostat and olodaterol inhaled both increase QTc interval. Use Caution/Monitor. Drugs that prolong the QTc interval and may potentiate the effects of beta2 agonists on the cardiovascular system; increased risk of ventricular arrhythmias

            • osilodrostat

              osilodrostat and vorinostat both increase QTc interval. Use Caution/Monitor.

            • osimertinib

              osimertinib and vorinostat both increase QTc interval. Use Caution/Monitor. Conduct periodic monitoring with ECGs and electrolytes in patients taking drugs known to prolong the QTc interval.

            • ozanimod

              ozanimod and vorinostat both increase QTc interval. Modify Therapy/Monitor Closely. The potential additive effects on heart rate, treatment with ozanimod should generally not be initiated in patients who are concurrently treated with QT prolonging drugs with known arrhythmogenic properties.

            • pasireotide

              vorinostat and pasireotide both increase QTc interval. Use Caution/Monitor.

            • perphenazine

              vorinostat and perphenazine both increase QTc interval. Use Caution/Monitor.

            • posaconazole

              vorinostat and posaconazole both increase QTc interval. Use Caution/Monitor.

            • primaquine

              primaquine and vorinostat both increase QTc interval. Use Caution/Monitor.

            • procainamide

              vorinostat and procainamide both increase QTc interval. Use Caution/Monitor.

            • prochlorperazine

              vorinostat and prochlorperazine both decrease QTc interval. Use Caution/Monitor.

            • promethazine

              vorinostat and promethazine both decrease QTc interval. Use Caution/Monitor.

            • quetiapine

              quetiapine, vorinostat. Either increases toxicity of the other by QTc interval. Use Caution/Monitor. Avoid use with drugs that prolong QT and in patients with risk factors for prolonged QT interval. Postmarketing cases show QT prolongation with overdose in patients with concomitant illness or with drugs known to cause electrolyte imbalance or prolong QT.

            • quinine

              vorinostat and quinine both increase QTc interval. Use Caution/Monitor.

            • ranolazine

              vorinostat and ranolazine both increase QTc interval. Use Caution/Monitor.

            • rilpivirine

              rilpivirine increases toxicity of vorinostat by QTc interval. Use Caution/Monitor. Rilpivirine should be used with caution when co-administered with a drug with a known risk of Torsade de Pointes.

            • risperidone

              vorinostat and risperidone both increase QTc interval. Use Caution/Monitor.

            • romidepsin

              vorinostat and romidepsin both increase QTc interval. Use Caution/Monitor.

            • selpercatinib

              selpercatinib increases toxicity of vorinostat by QTc interval. Use Caution/Monitor.

            • sertraline

              sertraline and vorinostat both increase QTc interval. Use Caution/Monitor.

            • siponimod

              siponimod and vorinostat both increase immunosuppressive effects; risk of infection. Use Caution/Monitor. Caution if coadministered because of additive immunosuppressive effects during such therapy and in the weeks following administration. When switching from drugs with prolonged immune effects, consider the half-life and mode of action of these drugs to avoid unintended additive immunosuppressive effects.

            • solifenacin

              solifenacin and vorinostat both increase QTc interval. Use Caution/Monitor.

              vorinostat and solifenacin both increase QTc interval. Use Caution/Monitor.

            • sorafenib

              sorafenib and vorinostat both increase QTc interval. Use Caution/Monitor.

            • sunitinib

              sunitinib and vorinostat both increase QTc interval. Use Caution/Monitor.

              vorinostat and sunitinib both increase QTc interval. Use Caution/Monitor.

            • tacrolimus

              tacrolimus and vorinostat both increase QTc interval. Use Caution/Monitor.

              vorinostat and tacrolimus both increase QTc interval. Use Caution/Monitor.

            • telavancin

              vorinostat and telavancin both increase QTc interval. Use Caution/Monitor.

            • triclabendazole

              vorinostat and triclabendazole both increase QTc interval. Use Caution/Monitor.

            • trifluoperazine

              vorinostat and trifluoperazine both decrease QTc interval. Use Caution/Monitor.

            • triptorelin

              vorinostat and triptorelin both increase QTc interval. Use Caution/Monitor.

            • valbenazine

              valbenazine and vorinostat both increase QTc interval. Use Caution/Monitor.

            • vardenafil

              vorinostat and vardenafil both increase QTc interval. Use Caution/Monitor.

            • venlafaxine

              vorinostat and venlafaxine both decrease QTc interval. Use Caution/Monitor.

            • vilanterol/fluticasone furoate inhaled

              vorinostat increases toxicity of vilanterol/fluticasone furoate inhaled by QTc interval. Use Caution/Monitor. Exercise caution when vilanterol coadministered with drugs that prolong QTc interval; adrenergic agonist effects on the cardiovascular system may be potentiated.

            • voclosporin

              voclosporin, vorinostat. Either increases effects of the other by QTc interval. Use Caution/Monitor.

            • voriconazole

              vorinostat and voriconazole both increase QTc interval. Use Caution/Monitor.

            Minor (2)

            • azithromycin

              azithromycin increases toxicity of vorinostat by QTc interval. Minor/Significance Unknown.

            • chloroquine

              chloroquine increases toxicity of vorinostat by QTc interval. Minor/Significance Unknown.

            Previous
            Next:

            Adverse Effects

            >10%

            Diarrhea (52%)

            Fatigue (52%)

            Nausea (41%)

            Dysguesia (28%)

            Thrombocytopenia (26%)

            Anorexia (24%)

            Weight loss (20.9%)

            Muscle spasms (19.8%)

            Alopecia (18.6%)

            Chills (16%)

            Dry mouth (16%)

            Increase serum Cr (16%)

            Dizziness (15%)

            Constipation (15%)

            Vomiting (15%)

            Anemia (14%)

            Peripheral edema (12.8%)

            Headache (11.6%)

            Pruritus (11.6%)

            Cough (10.5%)

            Upper respiratory infection (10.5%)

            Decreased appetite

            Pyrexia

            1-10%

            Prolonged QT interval (3.5-6%)

            Pulmonary embolism (4.7%)

            Previous
            Next:

            Warnings

            Contraindications

            Severe hepatic Impairment

            Cautions

            Congenital long QT syndrome, drugs/conditions that prolong QT interval; correct hypokalemia or hypomagnesemia before commencing treatment

            Thrombocytopenia and anemia may require dose modification or discontinuation; monitor blood counts every 2 weeks during first 2 months of therapy and monthly thereafter

            Severe thrombocytopenia with gastrointestinal bleeding reported with other HDAC inhibitors (e.g., valproic acid); monitor platelet counts more frequently

            Monitor for pertinent signs and symptoms of pulmonary embolism and deep vein thrombosis

            Potential for hyperglycemia; caution in diabetes; monitor blood glucose every 2 weeks during first 2 months of therapy and monthly thereafter

            Dose related anemia and thrombocytopenia may occur; modify dose or discontinue if reduction in platelets or Hgb

            Concomitant valproic acid

            May cause dizziness or fatigue

            Concomitant coumarin-derived anticoagulants

            Hepatic/renal impairment

            Nausea, vomiting and diarrhea; patients may require antiemetics, antidiarrheals, and fluid and electrolyte replacement to prevent dehydration

            Avoid pregnancy

            Drink at least 2 L of fluids daily

            Measure and correct abnormal electrolytes, creatinine, magnesium and calcium at baseline; monitor every 2 weeks during first 2 months of therapy and at least monthly during treatment

            Previous
            Next:

            Pregnancy & Lactation

            Pregnancy

            Based on mechanism of action and findings from animal studies, therapy can cause fetal harm when administered to a pregnant woman

            There are insufficient data in pregnant women to inform a drug-associated risk of major birth defects and miscarriage

            Advise pregnant women of potential risk to fetus

            Animal data

            • In animal reproduction studies, administration of drug to pregnant rats and rabbits during period of organogenesis caused adverse developmental outcomes at maternal exposures approximately 0.5 times the human exposure based on AUC0-24 hours

            Reproductive potential

            • Can cause fetal harm when administered to a pregnant woman

            Pregnancy testing

            • Perform pregnancy testing in females of reproductive potential within 7 days prior to initiating therapy

            Contraception

            • Females: Advise patients of reproductive potential to use effective contraception during treatment and for at least 6 months after the last dose
            • Males: Advise males with female partners of reproductive potential to use effective contraception and to avoid fathering a child during treatment with ZOLINZA and for at least 3 months after the last dose

            Infertility

            • Based on findings in animals, therapy has the potential to affect female fertility

            Lactation

            There are no data on presence of drug or its metabolites in human milk, effects on a breastfed child, or on milk production; because many drugs are excreted in human milk and because of potential for serious adverse drug reactions in a nursing child, advise lactating women not to breastfeed during treatment and for at least 1 week after last dose

            Pregnancy Categories

            A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA: Information not available.

            Previous
            Next:

            Pharmacology

            Mechanism of Action

            Histone deacetylase inhibitor for enzymes HDAC1, HDAC2, HDAC3, and HDAC6, which in turn alters chromatin structure and transcription factor activation; as a result, cell growth is terminated and apoptosis occurs

            Absorption

            Peak plasma time: 4 hr

            Peak plasma concentration (400 mg dose): 1.2±0.62 umol/L

            Fasted state has quicker peak time, but lower AUC and peak concentration

            Taken with a high fat meal increases extent of absorption by 33%

            Bioavailability: 43%

            Distribution

            Protein Bound: 71%

            Metabolism

            Liver

            Metabolites: Inactive

            Elimination

            Half-Life, Terminal: 2 hr

            Excretion: Urine 52%

            Previous
            Next:

            Administration

            Oral Administration

            Take with food

            Drink at least 2 L of fluids daily

            Previous
            Next:

            Images

            BRAND FORM. UNIT PRICE PILL IMAGE
            Zolinza oral
            -
            100 mg capsule

            Copyright © 2010 First DataBank, Inc.

            Previous
            Next:

            Patient Handout

            Patient Education
            vorinostat oral

            VORINOSTAT - ORAL

            (vor-IN-oh-stat)

            COMMON BRAND NAME(S): Zolinza

            USES: Vorinostat is used to treat a certain type of cancer (CTCL-cutaneous T-cell lymphoma). It works by slowing or stopping the growth of cancer cells.

            HOW TO USE: Read the Patient Information Leaflet if available from your pharmacist before you start taking vorinostat and each time you get a refill. If you have any questions regarding the information, ask your doctor or pharmacist.Take this medication by mouth with food as directed by your doctor, usually once daily. Swallow the capsules whole. Do not crush, chew, or open the capsules.Do not use capsules that are opened or crushed. If your skin or eyes come in contact with the powder inside the capsule, wash the area well with plenty of water and call your doctor.The dosage is based on your medical condition and response to treatment.To prevent dehydration while taking this medication, drink at least 8 glasses of water (8 ounces/240 milliliters each) throughout the day unless your doctor directs you otherwise.Do not increase your dose or take this medication more often than prescribed. Your condition will not improve any faster, and the risk of serious side effects may be increased.Since this drug can be absorbed through the skin and lungs, women who are pregnant or who may become pregnant should not handle this medication or breathe the dust from the capsules.Tell your doctor if your condition does not improve or if it worsens.

            SIDE EFFECTS: Tiredness, loss of appetite, weight loss, dizziness, dry mouth, change in the sense of taste, hair loss, headache, or cough may occur. If any of these effects last or get worse, tell your doctor or pharmacist promptly.Nausea, vomiting, and diarrhea can also occur and may be severe. Tell your doctor right away if these effects occur. In some cases, your doctor may prescribe medication to prevent or relieve them. Eating several small meals, not eating before treatment, or limiting activity may help to lessen the nausea and vomiting.People using this medication may have serious side effects. However, you have been prescribed this drug because your doctor has judged that the benefit to you is greater than the risk of side effects. Careful monitoring by your doctor may decrease your risk.Vomiting/diarrhea that doesn't stop may result in dehydration. Contact your doctor promptly if you notice any symptoms of dehydration, such as unusual decreased urination, unusual dry mouth/thirst, fast heartbeat, or dizziness/lightheadedness.This medication may rarely make your blood sugar rise, which can cause or worsen diabetes. Tell your doctor right away if you have symptoms of high blood sugar such as increased thirst/urination. If you already have diabetes, check your blood sugar regularly as directed and share the results with your doctor. Your doctor may need to adjust your diabetes medication, exercise program, or diet.This medication decreases bone marrow function, an effect that may lead to a low number of blood cells such as red cells, white cells, and platelets. This effect can cause anemia, decrease your body's ability to fight an infection, or cause easy bruising/bleeding. You may be at an increased risk for stomach/intestine bleeding if you are taking certain medications (see also Drug Interaction section). Tell your doctor right away if you develop any of the following unlikely symptoms: unusual tiredness, pale skin, signs of infection (such as sore throat that doesn't go away, fever, chills), easy bruising/bleeding, signs of stomach/intestine bleeding (such as black/bloody stools, vomit that contains blood or looks like coffee grounds, dizziness).Tell your doctor right away if you have any serious side effects, including: signs of low levels of magnesium/potassium/calcium in the blood (such as severe muscle spasms/cramps, irregular heartbeat, mental/mood changes, seizures).This medication may rarely cause blood clots (such as pulmonary embolism and deep vein thrombosis). You may be at increased risk for blood clots if you have a history of blood clots. Get medical help right away if any of these side effects occur: chest pain, pain/redness/swelling usually in the leg, trouble breathing.Get medical help right away if you have any very serious side effects, including: fast/irregular heartbeat, severe dizziness, fainting.A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.In the US -Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.

            PRECAUTIONS: Before taking this medication, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.Before using this medication, tell your doctor or pharmacist your medical history, especially of: liver disease, certain mineral imbalances (such as low levels of potassium or magnesium in the blood), blood clots.This drug may make you dizzy. Alcohol or marijuana (cannabis) can make you more dizzy. Do not drive, use machinery, or do anything that needs alertness until you can do it safely. Limit alcoholic beverages. Talk to your doctor if you are using marijuana (cannabis).Vorinostat may cause a condition that affects the heart rhythm (QT prolongation). QT prolongation can rarely cause serious (rarely fatal) fast/irregular heartbeat and other symptoms (such as severe dizziness, fainting) that need medical attention right away.The risk of QT prolongation may be increased if you have certain medical conditions or are taking other drugs that may cause QT prolongation. Before using vorinostat, tell your doctor or pharmacist of all the drugs you take and if you have any of the following conditions: certain heart problems (heart failure, slow heartbeat, QT prolongation in the EKG), family history of certain heart problems (QT prolongation in the EKG, sudden cardiac death).Low levels of potassium or magnesium in the blood may also increase your risk of QT prolongation. This risk may increase if you use certain drugs (such as diuretics/"water pills") or if you have conditions such as severe sweating, diarrhea, or vomiting. Talk to your doctor about using vorinostat safely.Before having surgery, tell your doctor or dentist about all the products you use (including prescription drugs, nonprescription drugs, and herbal products).Older adults may be more sensitive to the side effects of this drug, especially QT prolongation.Tell your doctor if you are pregnant or plan to become pregnant. You should have a pregnancy test before starting this medication. You should not become pregnant while using vorinostat. Vorinostat may harm an unborn baby. Females using this medication should ask about reliable forms of birth control while using this medication and for at least 6 months after stopping treatment. Males using this medication should ask about reliable forms of birth control while using this medication and for at least 3 months after stopping treatment. If you or your partner become pregnant, talk to your doctor right away about the risks and benefits of this medication.It is unknown if this drug passes into breast milk. Because of the possible risk to the infant, breast-feeding is not recommended while using this drug and for at least 1 week after stopping treatment. Consult your doctor before breast-feeding.

            DRUG INTERACTIONS: Drug interactions may change how your medications work or increase your risk for serious side effects. This document does not contain all possible drug interactions. Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) and share it with your doctor and pharmacist. Do not start, stop, or change the dosage of any medicines without your doctor's approval.Some products that may interact with this drug include: "blood thinners" (such as warfarin), valproic acid.

            OVERDOSE: If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center.

            NOTES: Do not share this medication with others.Laboratory and/or medical tests (such as complete blood count, kidney function, blood glucose levels, blood mineral levels including potassium/magnesium/calcium) should be performed periodically to monitor your progress or check for side effects. Consult your doctor for more details.

            MISSED DOSE: If you miss a dose, take it as soon as you remember. If it is near the time of the next dose, skip the missed dose. Take your next dose at the regular time. Do not double the dose to catch up.

            STORAGE: Store at room temperature away from light and moisture. Do not store in the bathroom. Keep all medications away from children and pets.Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company for more details about how to safely discard your product.

            Information last revised March 2022. Copyright(c) 2022 First Databank, Inc.

            IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.

            Previous
            Next:

            Formulary

            FormularyPatient Discounts

            Adding plans allows you to compare formulary status to other drugs in the same class.

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
            Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.